maridebart cafraglutide   Click here for help

GtoPdb Ligand ID: 13316

Synonyms: AMG 133 [3] | AMG-133 | AMG133 | MariTide
Compound class: Antibody
Comment: Maridebart cafraglutide (AMG133) is an anti-human gastric inhibitory polypeptide receptor (GIPR) antagonist antibody-peptide conjugate [1,3]. It has two attached glucagon-like peptide 1 (GLP-1) agonist peptides (cafraglutide). Maridebart cafraglutide is proposed to ellicit synergistic effects (antagonism of GIPR signalling and activation of GLP-1 receptor signalling) to regulate body weight for application as an anti-obesity modality [2-3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Maridebart cafraglutide (AMG133) is a clinical candidate for weight loss in obese patients.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04478708 Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity Phase 1 Interventional Amgen 3
NCT05669599 Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus Phase 2 Interventional Amgen
NCT06352892 A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight Phase 1 Interventional Amgen